Ciprofibrate therapy in patients with hypertriglyceridemia and low high density lipoprotein (HDL)-cholesterol: Greater reduction of non-HDL cholesterol in subjects with excess body weight (The CIPROAMLAT study)

Cardiovascular Diabetology

Volumn 3, Issue , 2004, Pages

  Aguilar Salinas, Carlos A ^a   Assis Luores Vale, Andréia ^b   Stockins, Benjamín ^c   Rengifo, Hector Mario ^d   Filho, José Dondici ^e   Neto, Abrahão Afiune ^f   Rabelo, Lísia Marcílio ^g   Torres, Kerginaldo Paulo ^h   de Oliveira, José Egídio Paulo ⁱ   Machado, Carlos Alberto ^j   Reyes, Eliana ^k   Saavedra, Victor ^l   Florenzano, Fernando ^m   Hernández, Ma Victoria ⁿ   Jiménez, Sergio Hernandez ^a   Ramírez, Erika ^a   Vazquez, Cuauhtémoc ^o   Salinas, Saul ^o   Hernández, Ismael ^p   Medel, Octavio ^p   Moreno, Ricardo ^q   Lugo, Paulo ^r   Alvarado, Ricardo ^s   Mehta, Roopa ^a   Gutierrez, Victor ^t   Gómez Pérez, Francisco J ^a   more..

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b Hospital Geral Socor   (Brazil)

^c UNIVERSIDAD DE LA FRONTERA   (Chile)

^d UNIVERSIDAD DEL VALLE   (Colombia)

^e Depto de Cardiologia   (Brazil)

^f Hospital Sao Salvador   (Brazil)

^g Fundacao Baiana de Cardiologia   (Brazil)

^h Procardio Depto de Aterosclerose   (Brazil)

ⁱ FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^j Ctro Ref Hipertensao Arter Diabet   (Brazil)

^k HOSPITAL DIPRECA   (Chile)

^l Unidad De Cardiología ^*  (Chile)

^m HOSPITAL DEL SALVADOR   (Chile)

ⁿ Hospital Clinico de la Fuerza Aerea de Chile   (Chile)

^o HOSPITAL DE CARDIOLOGÍA   (Mexico)

^p HOSPITAL JUÁREZ DE MÉXICO   (Mexico)

^q Hospital General Regional No 72   (Mexico)

^r INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^s Victoria de Durango   (Mexico)

^t Asociacion De Diabeticos De Chile   (Chile)

more..

Author keywords

Ciprofibrate; Fibrates; HDL cholesterol; Obesity; Triglycerides

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CIPROFIBRATE; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN BLOOD LEVEL; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYOPATHY; OBESITY; OPEN STUDY; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 13144303515     PISSN: 14752840     EISSN: None     Source Type: Journal    
DOI: 10.1186/1475-2840-3-8     Document Type: Article

References (25)

1. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F: High triglycerides/low high density lipoprotein cholesterol, ischemic electrocardiogram changes, and risk of ischemic heart disease. Am Heart J2002, 145:103-108.
2. Assmann G, Schulte H, Cullen P: New and classical risk factors - The Munster heart study (PROCAM). Eur J Med Res 1997, 2:237-242.
3. Stong K, Bonita R, the SuRF Report1: Surveillance of risk factors related to non-communicable diseases: Current status of global data. Geneva, World Health Organization; 2003.
4. Aguilar-Salinas CA, Olaiz G, Valles V, Ríos JM, Gómez Pérez FJ, Rull JA, Rojas R, Franco A, Sepúlveda J: High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nation wide survey. J Lipid Res 2001, 42: 298-1307.
5. Groop L, Orho-Melander M: The dysmetabolic syndrome. J Intern Med 2001, 250:105-120.
6. Bloomfield Rubins H, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas F, Linares E, Schaefer EJ, Schectman G, Wilt T, Wittes J, for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. Veterans Affairs High - Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341:410-418.
7. Robins S, Bloomfield Rubins H, Faas F, Schaefer E, Elam M, Anderson J, Collin D, on behalf of the VA-HIT Study Group: Insulin resistance and cardiovascular events with low HDL cholesterol. Diabetes Care 2003, 26:1513-1517.
8. Faergeman O: Hypertriglyceridemia and the fibrate trials. Curr Opin Lipidol 2000, 11:609-614.
9. Betteridge DJ, Khan M: Review of the guidelines for management of dislipidemia. Baillieres Clin Endocrinol Metab 1995, 9:867-890.
10. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and treatment of high cholesterol in adults (adult treatment panel III). JAMA 2001, 285:2486-2497.
11. Cattin L, Da Col PG, Feruglio FS, Finazzo L, Rimondi S, Descovich G, Manzato E, Zambon S, Crepaldi G, Siepi D: Efficacy of ciprofibrate in primary type II and IV hyperlipidemia: the Italian Multicenter Study. Clin Ther 1990, 12:482-488.
12. Betteridge DJ: Ciprofibrate: a profile. Postgrad Med J 1993, 69:S42-S47.
13. Bruckert E, Dejager S, Chapman MJ: Ciprofibrate therapy normalizes the atherogenic low density lipoprotein subspecies profile in combined hyperlipidemia. Atherosclerosis 1993, 100:91-102.
14. Goa K, Barradell L, Plosker G: Bezafibrate. Drugs 1996, 52:725-753.
15. Knipscheer H, de Valois C, van den Ende B, Wouter J, Kastelin J: Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidemia. Atherosclerosis 1996, 124(Suppl ):S75-S81.
16. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G: Insulin resistance and hypersecretion in obesity. J Clin Invest 1997, 100:1166-1173.
17. Schmidt MI, Duncan BB, Watson RL, Sharrett AR, Brancati FL, Heiss G: A metabolic syndrome in whites and African-Americans: the Atherosclerosis Risk in Communities baseline study. Diabetes Care 1996, 19:414-418.
18. Aguilar Salinas CA, Barrett H, Schonfeld G: Metabolic modes of action of statins in hyperlipoproteinemias. Atherosclerosis 1998, 141:203-207.
19. Hugh P, Barrett R, Watts GF: Kinetic studies of lipoprotein metabolism in the metabolic syndrome including effects of nutritional interventions. Curr Opin Lipidol 2003, 14: 1-68.
20. Shachter N: Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 2001, 12:297-304.
21. Fu T, Mukhopadhyay D, Davidson NO, Borensztajn J: The PPAR alpha agonist ciprofibrate inhibits apolipoprotein B mRNA editing in LDL receptor-deficient mice: Effects on plasma lipoproteins and the development of atherosclerotic lesions. J Biol Chem in press. 2004, Apr 27
22. Guerin M, Le Goff W, Frisdal E, Schneider S, Milosavljevic D, Bruckert E, Chapman MJ: Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux. J Clin Endocrinol Metab 2003, 88:3738-46.
23. Gaw A: Evidence based approach for the management of mixed hyperlipidemia. Atherosclerosis 1998, 137(Suppl ):S97-S100.
24. Barbier O, Torra IP, Duguay Y, Blanquart C, Fruchart JC, Glineur C, Staels B: Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2002, 22:717-26.
25. Tsuyuki RT, Bungard TJ: Poor adherence with hypolipidemic drugs: a lost opportunity. Pharmacotherapy 2001, 21: 76-582.